US-based drug discovery technology provider Schrödinger has partnered with Canada’s Centre for Drug Research and Development (CDRD) to create new cancer biologics, including immuno-oncology monoclonal antibodies.

The CDRC will supply targeted antibodies, which will be analysed by Schrödinger using its computation platform to prioritise the drug candidates and, if needed, enhance discovery.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Initially, the companies plan to work on an immune checkpoint target found on cancer stem cells.

Schrödinger president and CEO Ramy Farid said: “We’re excited to work with CDRD to aggressively translate scientific discoveries into innovative therapeutic products.

“This partnership is an important step forward in our efforts to extend the successes we’ve had in small molecule drug discovery.”

“This partnership is an important step forward in our efforts to extend the successes we’ve had in small molecule drug discovery to the development of novel biologics.”

As per the agreement, Schrödinger will predict physico-chemical liabilities and antibody humanisation in order to support hit triage and prioritisation, while CDRD will deliver critical molecular and physicochemical measurements for the antibody portfolio.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CDRD president and CEO Gordon McCauley said: “Schrödinger is the leader in applying in silico modelling to small molecule drug discovery, and we are excited to be a part of this unique collaboration leveraging those capabilities to speed biologics discovery.

“This collaboration also highlights our partnership with BCCA and our collaborative approaches as we work to advance groundbreaking cancer research from bench to bedside.”